CY1124685T1 - Εξατομικευμενα εμβολια για τον καρκινο - Google Patents

Εξατομικευμενα εμβολια για τον καρκινο

Info

Publication number
CY1124685T1
CY1124685T1 CY20211100945T CY211100945T CY1124685T1 CY 1124685 T1 CY1124685 T1 CY 1124685T1 CY 20211100945 T CY20211100945 T CY 20211100945T CY 211100945 T CY211100945 T CY 211100945T CY 1124685 T1 CY1124685 T1 CY 1124685T1
Authority
CY
Cyprus
Prior art keywords
cancer
tumor
patient
relates
present
Prior art date
Application number
CY20211100945T
Other languages
English (en)
Inventor
Ugur Sahin
Sebastian Kreiter
Mustafa DIKEN
Jan DIEKMANN
Cedrik Britten
John Castle
Martin LÖWER
Bernhard RENARD
Tana Omokoko
Johannes Hendrikus DE GRAAF
Michael Koslowski
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50185364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1124685(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2011/002576 external-priority patent/WO2012159643A1/en
Priority claimed from PCT/EP2012/002209 external-priority patent/WO2012159754A2/en
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of CY1124685T1 publication Critical patent/CY1124685T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Ecology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Artificial Intelligence (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται στην παροχή εμβολίων που είναι ειδικά για τον όγκο ενός ασθενούς και είναι δυνητικά χρήσιμα για ανοσοθεραπεία του πρωτοπαθούς όγκου καθώς και μεταστάσεις όγκου. Από μία άποψη, η παρούσα εφεύρεση σχετίζεται με μια μέθοδο παροχής εξατομικευμένου εμβολίου κατά του καρκίνου που περιλαμβάνει τα βήματα: (α) αναγνώριση σωματικών μεταλλάξεων για καρκίνο σε δείγμα όγκου καρκινοπαθούς για την παροχή υπογραφής μετάλλαξης καρκίνου του ασθενούς• και (β) παροχή εμβολίου με την υπογραφή της μετάλλαξης του καρκίνου που λαμβάνεται στο βήμα (α). Σε μια περαιτέρω άποψη, η παρούσα εφεύρεση αναφέρεται σε εμβόλια, τα οποία μπορούν να ληφθούν με την εν λόγω μέθοδο.
CY20211100945T 2011-05-24 2021-11-02 Εξατομικευμενα εμβολια για τον καρκινο CY1124685T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2011/002576 WO2012159643A1 (en) 2011-05-24 2011-05-24 Individualized vaccines for cancer
EP2012000006 2012-01-02
EP12723117.3A EP2714071B1 (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer
PCT/EP2012/002209 WO2012159754A2 (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer

Publications (1)

Publication Number Publication Date
CY1124685T1 true CY1124685T1 (el) 2022-07-22

Family

ID=50185364

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20191100986T CY1122110T1 (el) 2011-05-24 2019-09-18 Εξατομικευμενα εμβολια για τον καρκινο
CY20211100945T CY1124685T1 (el) 2011-05-24 2021-11-02 Εξατομικευμενα εμβολια για τον καρκινο
CY20231100248T CY1126128T1 (el) 2011-05-24 2023-05-25 Εξατομικευμενα εμβολια για τον καρκινο

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20191100986T CY1122110T1 (el) 2011-05-24 2019-09-18 Εξατομικευμενα εμβολια για τον καρκινο

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20231100248T CY1126128T1 (el) 2011-05-24 2023-05-25 Εξατομικευμενα εμβολια για τον καρκινο

Country Status (8)

Country Link
EP (4) EP2714071B1 (el)
CY (3) CY1122110T1 (el)
DK (1) DK3473267T3 (el)
HR (1) HRP20191535T1 (el)
ME (1) ME03498B (el)
PL (2) PL3473267T3 (el)
RS (1) RS59369B1 (el)
SI (1) SI2714071T1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2714071T1 (sl) 2011-05-24 2019-11-29 Biontech Rna Pharmaceuticals Gmbh Individualizirana cepiva proti raku
CN103608033B (zh) 2011-05-24 2016-06-15 生物技术公司 用于癌症的个体化疫苗
AU2016339924B2 (en) * 2015-10-12 2020-01-02 Nantomics, Llc Compositions and methods for viral cancer neoepitopes
SG11202103243PA (en) * 2018-11-15 2021-04-29 Nouscom Ag Selection of cancer mutations for generation of a personalized cancer vaccine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
AU1774299A (en) 1997-12-24 1999-07-19 Imperial Cancer Research Technology Limited Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
PT1214097E (pt) * 1999-09-16 2009-10-19 Eisai Inc Ácidos nucleicos que codificam polipéptidos de poliepitopos
EP1832603B1 (de) 2001-06-05 2010-02-03 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt, enkodierend für ein bakterielles Antigen sowie deren Verwendung
JP2005510244A (ja) * 2001-11-26 2005-04-21 ザ・ユニヴァーシティ・オヴ・クイーンズランド フラビウイルスワクチン送達系
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AU2003235707A1 (en) * 2002-01-18 2003-07-30 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
DE10335833A1 (de) * 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
IL158140A0 (en) 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
KR102017898B1 (ko) * 2010-05-14 2019-09-04 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
SI2714071T1 (sl) 2011-05-24 2019-11-29 Biontech Rna Pharmaceuticals Gmbh Individualizirana cepiva proti raku

Also Published As

Publication number Publication date
PL3473267T3 (pl) 2022-01-10
SI2714071T1 (sl) 2019-11-29
RS59369B1 (sr) 2019-11-29
CY1126128T1 (el) 2023-11-15
HRP20191535T1 (hr) 2019-11-29
EP3473267A1 (en) 2019-04-24
EP2714071B1 (en) 2019-07-10
EP3473267B1 (en) 2021-09-08
EP4223311A1 (en) 2023-08-09
EP3892295B1 (en) 2023-04-26
EP2714071A2 (en) 2014-04-09
CY1122110T1 (el) 2020-11-25
DK3473267T3 (da) 2021-10-18
EP3892295A1 (en) 2021-10-13
ME03498B (me) 2020-04-20
PL2714071T3 (pl) 2019-12-31

Similar Documents

Publication Publication Date Title
CY1124685T1 (el) Εξατομικευμενα εμβολια για τον καρκινο
MX2020011767A (es) Vacunas individualizadas para el cancer.
CY1124176T1 (el) Προβλεψη ανοσογονiκοτητας των επιτοπων των t κυτταρων
CY1124558T1 (el) Προβλεψη επιτοπων τ κυτταρων χρησιμων για εμβολιασμο
CY1125084T1 (el) Εμβολια νουκλεϊκου οξεος
CY1121934T1 (el) Αντισωματα anti-fcrn
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1123769T1 (el) Νουκλεϊκα οξεα για την αγωγη αλλεργιων
CY1122005T1 (el) Ανθρωπινα αντισωματα κατα toy pd-l1
CY1123884T1 (el) Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων
CY1121517T1 (el) Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib
CY1119925T1 (el) Aνti-cd40 αντισωματα, χρησεις και μεθοδοι
CY1124028T1 (el) Συνθεσεις και μεθοδοι για τα αντισωματα που στοχευουν την ερο
CY1118899T1 (el) Ενωσεις ενεδιυνης, συζευγματα εξ’ αυτων, και χρησεις και μεθοδοι δια τουτων
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CY1123743T1 (el) Αντισωμα igf-ir και χρηση του ως ουσια-οχημα διευθυνσιοδοτησης για την αγωγη του καρκινου
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1123520T1 (el) Μεθοδοι για την προβλεψη της χρησιμοτητας των νεων αντιγονων για ανοσοθεραπεια
MX2017004039A (es) Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso.
IN2014KN00920A (el)
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
CY1122850T1 (el) Υπερδιακλαδισμενος πολυ (βητα-αμινοεστερας) για γονιδιακη θεραπεια
CY1121550T1 (el) Ενωσεις πυριδινης πλαδιενολιδης και μεθοδοι χρησης
BR112016025035A2 (pt) imunoterapia contra diversos tumores hematológicos, como a leucemia mieloide aguda (aml)
PE20201284A1 (es) Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc)